Latest news with #PanGIA
Yahoo
3 days ago
- Health
- Yahoo
ASCO25: PanGIA Biotech's AI-based urine test for prostate cancer hits trial success
With early detection of prostate cancer recognised as a critical part in reducing the disease's mortality rate, PanGIA Biotech has shared results from a study validating its artificial intelligence (AI)-based liquid biopsy in vitro diagnostic (IVD) for detecting early prostate cancer from urine samples. The US company's detection methodology involves analysing urinary biosignatures using AI and machine learning models, which the company asserts may prove beneficial over invasive biopsies or blood-based tests that may miss early-stage cases while also eliminating the need for sequencing. PanGIA's prospective study involved 197 biopsy-confirmed prostate cancer patients and 84 healthy controls, with the test demonstrating strong performance in detecting intermediate- and low-grade cancers, and high recall (>0.89) across Gleason scores 6 through 10. The AI/ML classification model was also found to be effective as measured by F1 score. The study's findings were presented at the American Society of Clinical Oncology (ASCO) 2025 meeting, taking place in Chicago, Illinois between 30 May and 3 June. 'This study confirms what we've believed from the start: there's power in non-invasive, data-driven diagnostics,' PanGIA CEO Holly Magliochetti. 'Our platform helps clinicians detect prostate cancer when intervention is most effective – without costly or invasive procedures.' Past research indicates that with early detection, the five-year survival rate for prostate cancer is over 99%. According to GlobalData's Pipeline Products database, there are 142 prostate cancer IVDs at active stages of development globally. Growing at a CAGR of 3.5%, the overall global IVD market is forecast to reach a valuation of around $45.9m by 2024, up from $32.4m in 2024, as per GlobalData analysis. In other prostate cancer news from ASCO 2025, researchers from the UK's Institute of Cancer Research (ICR) and University College London (UCL) demonstrated that an AI-based test developed by US-based Artera can help identify which men with non-metastatic high-risk prostate cancer are most likely to benefit from being administered abiraterone. A recent large report by Philips on the passage of AI adoption and innovation in healthcare reflected that while clinicians are chiefly on board with the AI and recognise its value in healthcare settings, 46% of respondents stated that slow adoption of AI was contributing towards missed opportunities for early diagnosis and intervention. "ASCO25: PanGIA Biotech's AI-based urine test for prostate cancer hits trial success" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Wire
4 days ago
- Business
- Business Wire
PanGIA Biotech Unveils AI-Driven Urine Test Data for Early Prostate Cancer Detection at ASCO 2025
CHICAGO--(BUSINESS WIRE)--PanGIA Biotech, a leader in non-invasive cancer diagnostics, presented findings at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) from a prospective, multi-center validation study evaluating its AI-powered, urine-based platform for early-stage prostate cancer detection. The study, Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080) is the first to clinically validate PanGIA®'s novel approach pairing proprietary chemistry with machine learning. Share The study, Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080), is the first to clinically validate PanGIA®'s novel approach—pairing proprietary chemistry with machine learning to detect cancer-specific biosignatures from a single, non-invasive urine sample. 'This study confirms what we've believed from the start: there's power in non-invasive, data-driven diagnostics,' said Holly Magliochetti, CEO of PanGIA Biotech. 'Our platform helps clinicians detect prostate cancer when intervention is most effective—without costly or invasive procedures.' Key findings presented included: Study Cohort: 197 biopsy-confirmed prostate cancer patients and 84 healthy controls. Classifier Performance: Achieved an F1 score of 0.843 with a recall of 0.967 in distinguishing cancer from non-cancer subjects. Gleason Score Cohorts: Maintained high recall (>0.89) across Gleason scores 6 through 10, with F1 scores ranging from 0.799 to 0.838. Non-Invasive Advantage: Demonstrated strong performance in detecting intermediate- and low-grade cancers, offering a less invasive alternative to traditional diagnostics. Unlike invasive biopsies or blood-based tests that often miss early-stage cases, PanGIA's approach analyzes urinary biosignatures using proprietary AI models—eliminating the need for sequencing and enabling cost-effective, globally scalable testing. Previously published in The Analyst, a journal of the Royal Society of Chemistry¹, the PanGIA platform is designed for diverse healthcare environments and holds promise for broad global adoption. About PanGIA Biotech PanGIA Biotech develops AI-integrated, urine-based liquid biopsy solutions designed for global scalability. The PanGIA® platform supports early detection, monitoring, and disease management—including cancer as early as Stage 1. With machine learning at its core, the platform deciphers biomolecular patterns to deliver accurate diagnostic insights. Backed by patents and peer-reviewed research, PanGIA is committed to reshaping healthcare through innovation. Learn more at ¹ Lim FB, et al. 'A Colorimetric Chemical Tongue Detects And Distinguishes Between Multiple Analytes.' The Analyst. 2022;147(23):5283–5292. doi:10.1039/D2AN01615J
Yahoo
4 days ago
- Health
- Yahoo
PanGIA Biotech Unveils AI-Driven Urine Test Data for Early Prostate Cancer Detection at ASCO 2025
CHICAGO, June 02, 2025--(BUSINESS WIRE)--PanGIA Biotech, a leader in non-invasive cancer diagnostics, presented findings at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO) from a prospective, multi-center validation study evaluating its AI-powered, urine-based platform for early-stage prostate cancer detection. The study, Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080), is the first to clinically validate PanGIA®'s novel approach—pairing proprietary chemistry with machine learning to detect cancer-specific biosignatures from a single, non-invasive urine sample. "This study confirms what we've believed from the start: there's power in non-invasive, data-driven diagnostics," said Holly Magliochetti, CEO of PanGIA Biotech. "Our platform helps clinicians detect prostate cancer when intervention is most effective—without costly or invasive procedures." Key findings presented included: Study Cohort: 197 biopsy-confirmed prostate cancer patients and 84 healthy controls. Classifier Performance: Achieved an F1 score of 0.843 with a recall of 0.967 in distinguishing cancer from non-cancer subjects. Gleason Score Cohorts: Maintained high recall (>0.89) across Gleason scores 6 through 10, with F1 scores ranging from 0.799 to 0.838. Non-Invasive Advantage: Demonstrated strong performance in detecting intermediate- and low-grade cancers, offering a less invasive alternative to traditional diagnostics. Unlike invasive biopsies or blood-based tests that often miss early-stage cases, PanGIA's approach analyzes urinary biosignatures using proprietary AI models—eliminating the need for sequencing and enabling cost-effective, globally scalable testing. Previously published in The Analyst, a journal of the Royal Society of Chemistry¹, the PanGIA platform is designed for diverse healthcare environments and holds promise for broad global adoption. About PanGIA Biotech PanGIA Biotech develops AI-integrated, urine-based liquid biopsy solutions designed for global scalability. The PanGIA® platform supports early detection, monitoring, and disease management—including cancer as early as Stage 1. With machine learning at its core, the platform deciphers biomolecular patterns to deliver accurate diagnostic insights. Backed by patents and peer-reviewed research, PanGIA is committed to reshaping healthcare through innovation. Learn more at ¹ Lim FB, et al. "A Colorimetric Chemical Tongue Detects And Distinguishes Between Multiple Analytes." The Analyst. 2022;147(23):5283–5292. doi:10.1039/D2AN01615J View source version on Contacts Media Contact Joy CappsMedia@ 843-730-3857
Business Wire
30-04-2025
- Business
- Business Wire
PanGIA Biotech Announces Upcoming ASCO 2025 Poster Presentation of Collaborative Research
DELRAY BEACH, Fla.--(BUSINESS WIRE)--PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc., and Genetics Institute of America has been accepted for presentation at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place May 30–June 3, 2025, in Chicago, Illinois. Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080) has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted Agents and Share The abstract, titled Development and validation of an AI-enabled prediction of prostate cancer (PCa) using urine-based liquid biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology. The presentation highlights collaborative research contributing to PanGIA's AI-driven, urine-based diagnostic platform. The work integrates biomolecular pattern analysis and machine learning to support the development of scalable, non-invasive solutions in cancer care. ASCO 2025 Presentation Details Date: June 2, 2025 Time: 1:30 – 4:30 p.m. CDT Location: McCormick Place, Chicago, IL 'This presentation reflects our focus on developing non-invasive, scalable diagnostics rooted in the promise of liquid biopsy innovation,' said Holly Magliochetti, CEO of PanGIA Biotech. 'We remain committed to advancing technologies that may support earlier cancer detection and improve access to care globally.' Co-authors on the abstract include researchers from PanGIA Biotech, Entopsis Inc., and the Genetics Institute of America. About PanGIA Biotech PanGIA Biotech develops AI-integrated liquid biopsy technology designed for global scalability. The PanGIA® platform is a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights. PanGIA's technology is grounded in peer-reviewed research and R&D success, supported by patents to the company for global diagnostic development. With a steadfast commitment to research and innovation, PanGIA's vision is to revolutionize disease detection and improve healthcare worldwide. For more information, visit
